Piflufolastat (18F)
A radiopharmaceutical used in PET imaging of prostate cancer
Piflufolastat (18F), also known as 18F-DCFPyL, is a radiopharmaceutical used in positron emission tomography (PET) imaging to detect prostate cancer. It is a fluorine-18 labeled small molecule that targets the prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.
Mechanism of Action
Piflufolastat (18F) functions by binding to PSMA, a transmembrane protein that is significantly upregulated in prostate cancer cells. The fluorine-18 isotope emits positrons, which are detected by PET scanners to produce detailed images of the distribution of the radiopharmaceutical in the body. This allows for the visualization of prostate cancer lesions with high specificity and sensitivity.
Clinical Use
Piflufolastat (18F) is primarily used in the detection and localization of prostate cancer metastases. It is particularly useful in cases of biochemical recurrence, where there is a rise in prostate-specific antigen (PSA) levels following initial treatment, but conventional imaging fails to locate the cancer. The high affinity of piflufolastat for PSMA enables the detection of even small metastatic lesions.
Administration
The radiopharmaceutical is administered intravenously. The typical dose is calculated based on the patient's body weight and the specific activity of the radiopharmaceutical. After administration, patients are scanned using a PET scanner, usually within 60 to 120 minutes post-injection, to allow for optimal imaging.
Safety and Side Effects
Piflufolastat (18F) is generally well-tolerated. The most common side effects are related to the injection process, such as pain at the injection site. As with all radiopharmaceuticals, there is a small risk of radiation exposure, but the benefits of accurate cancer detection typically outweigh these risks.
Development and Approval
Piflufolastat (18F) was developed to improve the detection of prostate cancer metastases. It received approval from the Food and Drug Administration (FDA) for use in PET imaging of prostate cancer, providing a valuable tool for clinicians in the management of this disease.
Related Pages
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
